Lyra Therapeutics, Inc.
LYRADelisted Apr 20, 2026- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001327273
Lyra Therapeutics, Inc. was delisted on Apr 20, 2026; its insiders filed their last Form 4 on May 15, 2026; 23 institutions reported holding it in 13F filings for Q4 2025, worth $747.3K in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 23
- Q4 2025, −3 vs. previous quarter
- 13F value
- $747.3K
- Reported value at the end of Q4 2025
- Superinvestors holding
- 0
- At the end of Q4 2025
Superinvestors holding LYRA, Q4 2025
No superinvestor reported holding LYRA at the end of Q4 2025.
Latest insider trades
Open-market purchases and sales by Lyra Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 8, 2026 (view filing) | Jan 6 | 2 days | Cavalier JasonChief Financial Officer | SSale | −769 | $3.36 | −$2.58K | −0.1%518.5K after | 10b5-1 |
| Jan 8, 2026 (view filing) | Jan 6 | 2 days | Palasis MariaPresident & CEO | SSale | −1.70K | $3.36 | −$5.72K | −0.2%1.10M after | 10b5-1 |
| Nov 13, 2025 (view filing)5:07 PM ET | Nov 11-13 | 2 days | Edelman Joseph and 3 others10% Owner | SSale | −45.9K | $3.98 | −$182.5K | −76.6%14.0K after | 6 lots |
| Nov 10, 2025 (view filing)5:08 PM ET | Nov 6-10 | 4 days | Edelman Joseph and 3 others10% Owner | SSale | −70.4K | $4.89 | −$344.2K | −79.0%18.7K after | 6 lots |
| Jul 14, 2025 (view filing) | Jul 10 | 4 days | Palasis MariaPresident & CEO | SSale | −1.56K | $8.91 | −$13.9K | −0.1%1.10M after | 10b5-1 |
| Jul 14, 2025 (view filing) | Jul 10 | 4 days | Cavalier JasonChief Financial Officer | SSale | −684 | $8.91 | −$6.09K | −0.1%519.3K after | 10b5-1 |
| Nov 13, 2023 (view filing) | Nov 10 | 3 days | Waksal HarlanExecutive Chair | PPurchase | +25.0K | $2.96 | +$74.0K | +10.6%262.0K after | |
| Jun 2, 2023 (view filing)4:15 PM ET | May 31 | 2 days | North Bridge Venture Partners V-B LP and 6 others10% Owner | PPurchase | +1.81M | $2.43 | +$4.39M | +252.0%2.52M after | 3 lotsDuplicate filing |
| Jun 2, 2023 (view filing)4:15 PM ET | May 31 | 2 days | North Bridge Venture Partners V-B LP and 6 others10% Owner | PPurchase | +902.7K | $0.125 | +$112.8K | –601.8K after | Derivative3 lotsDuplicate filing |
| Jun 2, 2023 (view filing)4:11 PM ET | May 31 | 2 days | Anderson Edward TDirector, 10% Owner | PPurchase | +1.81M | $2.43 | +$4.39M | +252.0%2.52M after | 3 lots |
Top 10 13F holders, Q4 2025
The largest institutional positions in Lyra Therapeutics, Inc. at the end of Q4 2025; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sabby Management, LLC | 175,158 | $539.5K | 4.50% | +47,534+37.2% | Added |
| Ikarian Capital, LLC | 21,161 | $65.2K | 0.01% | 00.0% | Unchanged |
| DRW Securities, LLC | 16,812 | $51.8K | 0.00% | +16,812 | New |
| Geode Capital Management, LLC | 12,249 | $37.7K | 0.00% | +1,263+11.5% | Added |
| Artia Global Partners LP | 8,756 | $27.0K | 0.00% | +8,756 | New |
| BlackRock, Inc. | 2,394 | $7.37K | 0.00% | +704+41.7% | Added |
| Tower Research Capital LLC (TRC) | 2,191 | $6.75K | 0.00% | +1,657+310.3% | Added |
| Royal Bank of Canada | 1,953 | $6.00K | 0.00% | +628+47.4% | Added |
| UBS Group AG | 675 | $2.08K | 0.00% | −3,326−83.1% | Reduced |
| EverSource Wealth Advisors, LLC | 338 | $1.04K | 0.00% | −7−2.0% | Reduced |
Holders of 5% or more of LYRA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Lyra Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Perceptive Advisors LLC | 13D/A | 15.55%255.8K shares | – | Aug 14, 20251 filing | Aug 14, 2025 | SEC |
| Sabby Management, LLC | 13G | 9.90%175.2K shares | New | Jan 20, 20261 filing | Jan 20, 2026 | SEC |